Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Breaking & Recent News Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical stage pharmaceutical company. The Company is engaged in the research and development of light, radiation, sound and/or drug-activated small molecule compounds, their associated drug formulations and the light systems that activate them, with a primary objective of efficacy and a secondary objective of safety in the destruction of various... see more

Recent & Breaking News (TSXV:TLT)

Theralase(R) Interim Clinical Data to be Presented at the 2025 AUA Annual Meeting

ACCESS Newswire 9 days ago

BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma-In-Situ: A Patient's Guide

Trevor Abes  December 23, 2024

Theralase(R) Launches Three New Clinical Study Sites in USA

ACCESS Newswire December 9, 2024

Theralase(R) Launches New Clinical Study Site in Canada

ACCESS Newswire December 5, 2024

Theralase(R) Release's 3Q2024 Financial Statements

ACCESS Newswire November 27, 2024

Theralase(R) Closes Non-Brokered Private Placement

ACCESS Newswire November 15, 2024

Theralase(R) Extends Warrants

ACCESS Newswire November 12, 2024

Three Canadian small-caps stocks for a contrarian investment

Trevor Abes  October 11, 2024

Latest data from bladder cancer study to propel future growth

Jocelyn Aspa October 10, 2024

Theralase’s bladder cancer drug under investigation in clinical study

Jonathon Brown October 7, 2024

Theralase(R) Provides Update on Bladder Cancer Clinical Study

ACCESS Newswire October 7, 2024

Theralase(R) Closes Non-Brokered Private Placement and Issues Stock Options

ACCESS Newswire September 24, 2024

Theralase(R) Extends Warrants

ACCESS Newswire September 19, 2024

Ruvidar(TM) Proven More Effective Than Acyclovir in Destruction of Herpes Simplex Virus

ACCESS Newswire September 3, 2024

Rutherrin(R) Increases Efficacy of Chemotherapy for Lung Cancer

ACCESS Newswire August 28, 2024

Pharma stock Theralase paves way for in-home cancer treatment

Trevor Abes  August 21, 2024

Theralase(R) Demonstrates Unique Ability to Activate Rutherrin(R) With Diabetes Drug

ACCESS Newswire August 21, 2024

Theralase(R) Release's 2Q2024 Financial Statements

ACCESS Newswire August 12, 2024

Theralase(R) Closes $CAN 775,000 in First Tranche of Non-Brokered Private Placement

ACCESS Newswire July 8, 2024

Rutherrin(R) Repurposes Non-Cancer Drugs for Cancer Therapy

ACCESS Newswire June 20, 2024